Skip to content

1 December 2021

Med tech leads the way at RSNA (Radiological Society of North America)

Congratulations to all the presenters at this week’s RSNA 2021 conference.

This is a globally-significant radiology conference that highlights the leading edge of science, technology and practice in medical imaging.

More than 19,000 attendees met in Chicago, with another 4,000 virtual delegates, to discuss advances in radiology.

Together they had the opportunity to experience more than 2,000 scientific presentations, 1,500 educational exhibits and more than 300 educational courses.

It is at this globally significant conference that Siemens will also present for the first time at a tradeshow, the NAEOTOM Alpha, the world’s first photon-counting CT machine.

According to Siemens, this represents “a 20-year journey in order to completely reinvent the established technology in the field of computed tomography”.

Advancing technology in radiology

Technology is at the core of radiology practice. The number of presentations at RSNA 2021 highlights the importance of AI-based solutions.

AI is forging new ways to visualise and process medical information. Research has highlighted a hunger for information from medical imaging professionals.

We know the radiology industry is keen for new technology and are early adopters, with many believing it will speed up reporting and diagnosis times.

We’ve seen how it was standing room only at the machine learning challenge recognition event.

At RSNA, delegates will be able to learn from presentations that delve into the opportunity of AI and technology.

This includes "Ultrasound + AI in Breast Imaging: Prospective Clinical Use Impact & Experience: GE Healthcare", "Artificial Intelligence in the Hands of Medical Imaging and Radiation Therapy Professionals: The Current Status of AI in Our Practice", and "The AI Revolution: Recent Advancements in Computer Vision and Natural Language Processing in Medical Imaging".

Artrya supports you

Artrya Salix is listed on the Australian Register of Therapeutic Goods and is a non-invasive solution to assess vulnerable plaque, stenosis and calcium score.

Innovation in medical technology is at the core of our organisation.

Artrya Salix is an AI solution that supports assessment and reporting of coronary artery disease biomarkers, including critical vulnerable plaques. It is easy to use at the point-to-care at the medical imaging practice.

The software has used high-quality data and reports from the University of Ottawa Heart Institute and others. Artrya Salix can non-invasively assess coronary artery disease using complex algorithms based on triple-read coronary computed tomography angiography (CCTA) scans.

Not only does Salix detect stenosis and determine the coronary artery calcium (CAC) score, it can determine the presence of vulnerable plaque.

As we heard at RSNA, the presence of vulnerable plaques is a key factor in heart attack risk.

Keck School of Medicine of USC Professor of Clinical Radiology, Professor Farhood Saremi, told the delegates the majority of acute coronary syndrome events were the result of sudden luminal thrombosis due to plaque rupture in approximately two third of cases, or plaque erosion in the remainder.

He made the provocative statement that the identification of key plaque biomarkers was imperative for risk stratification, with CCTA a valuable tool for patients with high-risk plaques, compared to intravascular ultrasound (IVUS).

This could allow CCTA to become a surrogate of IVUS.

We believe these AI and technology enhancements will advance patient outcomes, improve healthcare systems and support clinicians. Ultimately these advances will reduce the burden of coronary artery disease while increasing the accessibility to healthcare for all.